Natixis’s Pfizer PFE Stock Holding History

Natixis’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-103	Closed	-$5K	–	1152
2022 Q2	$5K	Buy	+103	New	+$5.25K	﹤0.01%	1099

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Natixis's PFE Position: Q1 2026 in Review

Natixis reduced its Pfizer (PFE) stake by 66% in Q1 2026, selling an estimated $99M and leaving 1,912,234 shares worth $53.7M. The position accounts for 0.19% of the portfolio, ranked #75.

Natixis first reported a position in PFE in Q2 2013 and has held it in 49 quarters since. The position peaked at $258M in Q2 2019. 2,935 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

Natixis held 1,912,234 shares of Pfizer worth $53.7M as of Q1 2026.
Natixis sold 3,717,590 Pfizer shares in Q1 2026, an estimated $99M.
Pfizer made up 0.19% of Natixis's portfolio in Q1 2026, its #75 holding.
Natixis first reported a position in Pfizer in Q2 2013 and has held it in 49 quarters since.
Natixis's Pfizer position peaked at $258M in Q2 2019.
2,935 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.